Evident Vascular develops IVUS (intravascular ultrasound), an essential diagnostic image-guided therapy tool for the treatment of peripheral arterial and venous disease, enabling intraluminal visualization.

Evident Vascular

Evident Vascular, Inc., is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions.

Evident Vascular, Inc.

📢 ACC 2024 🗞️

Large prospective RCT demonstrates IVUS-guided DCB intervention in fempop 🦵 disease provides significantly improved clinical outcomes! 

Now if only there was a next generation IVUS platform with better image quality, improved ease of use, and AI-enabled capabilities that clinicians actually wanted to use…

Check out —> Evident Vascular, Inc.  

Cc: Howard Rosen

Scientific Advisory Board Member Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM is the leading author of a new study published in the Journal of Society for Cardiovascular Angiography & Interventions (SCAI). The report underscores the need to broaden the adoption of intravascular ultrasound (#IVUS) in peripheral arterial and deep venous interventions, emphasizing its crucial role in advancing patient care.

Evident Vascular CEO Howard Rosen, Vensana Capital Co-Founder and Managing Partner Justin Klein, MD, JD and Vensana Capital Partner Cynthia Yee shared insights and perspective in a new MedTech Strategist article. Together, they weighed in on the implications of this research and highlighted ongoing efforts to develop an advanced solution that will enable more accurate diagnosis and treatment and provide better clinical outcomes.

“Our aim is to significantly enhance adoption rates by streamlining workflow, improving imaging quality for better interpretation, and integrating AI to simplify the process,” Rosen said. “The driving force of Evident Vascular is to address the existing shortcomings and obstacles that are preventing clinicians from utilizing IVUS to its full potential for the benefit of their patients.” 
 
#MedicalInnovation #CardiovasularHealth #PVD #CVD #intravascularimaging #imageguidedtherapy #startup #medtech

We are #hiring! 
We’re looking for individuals to join our R&D and Quality teams. To find out more about these positions at Evident Vascular check out this link: https://lnkd.in/guJSTXt4

#medtech #IVUS #startup #imaging

Today we announce the establishment of our Scientific Advisory Board. Read press release here: tinyurl.com/2p83zus8

We are proud to have such an esteemed group of clinical experts working with us and providing important guidance and insights as we develop a best-in-class IVUS platform designed to meet the specific needs of the interventionalist. Thank you to Ehrin Armstrong, Venita Chandra, Paul Gagne, Mark Garcia, S. Jay Mathews, MD, MS, FACC, FSCAI, Mahmood Razavi, John Rundback, Peter Schneider, and Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM. 

We also are pleased to announce that Bruce Shook  an exceptionally accomplished medtech entrepreneur, has joined our Board of Directors as an independent director.

#VIVA2023 #intravascular #imaging #intravascularimaging #imageguidedtherapy #ultrasound #ivus #peripheral #vascular #coronary #cardiovascular #pvd #cvd #startup #medtech

Introducing Evident Vascular! Today we exit stealth mode with a $35M Series A round from Vensana Capital and are poised to transform the future of #intravascular #imaging. 

We are developing a state-of-the-art intravascular #ultrasound (#IVUS) platform technology designed initially for #peripheral #vascular interventions, with future capability for #coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, our technology is designed to expand the adoption of IVUS.  

Based in Silicon Valley, our founding executive team, Howard Rosen, Patrick Phillips and Danielo Piazza, have deep experience in #peripheral #vascular and #cardiovascular markets. Follow us to hear more about what we are doing and for additional announcements coming soon.

Read our press release and learn more about our company: tinyurl.com/yvw7rzvw
#PVD, #CVD, #intravascularimaging, #imageguidedtherapy, #startup, #medtech

EVID

COM:EVIDENTVASCULAR

Evident Vascular